"Tumor Microenvironment" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The milieu surrounding neoplasms consisting of cells, vessels, soluble factors, and molecules, that can influence and be influenced by, the neoplasm's growth.
| Descriptor ID |
D059016
|
| MeSH Number(s) |
G04.366.500
|
| Concept/Terms |
Tumor Microenvironment- Tumor Microenvironment
- Microenvironment, Tumor
- Microenvironments, Tumor
- Tumor Microenvironments
Cancer Microenvironment- Cancer Microenvironment
- Cancer Microenvironments
- Microenvironment, Cancer
- Microenvironments, Cancer
|
Below are MeSH descriptors whose meaning is more general than "Tumor Microenvironment".
Below are MeSH descriptors whose meaning is more specific than "Tumor Microenvironment".
This graph shows the total number of publications written about "Tumor Microenvironment" by people in this website by year, and whether "Tumor Microenvironment" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 2 | 1 | 3 |
| 2011 | 3 | 4 | 7 |
| 2012 | 5 | 8 | 13 |
| 2013 | 9 | 4 | 13 |
| 2014 | 4 | 7 | 11 |
| 2015 | 15 | 8 | 23 |
| 2016 | 8 | 13 | 21 |
| 2017 | 12 | 11 | 23 |
| 2018 | 11 | 17 | 28 |
| 2019 | 17 | 18 | 35 |
| 2020 | 5 | 19 | 24 |
| 2021 | 13 | 29 | 42 |
| 2022 | 3 | 32 | 35 |
| 2023 | 2 | 30 | 32 |
| 2024 | 17 | 26 | 43 |
| 2025 | 3 | 5 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Microenvironment" by people in Profiles.
-
YTHDFs as radiotherapy checkpoints in tumor immunity. J Exp Med. 2025 Aug 04; 222(8).
-
Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response. Blood. 2025 May 22; 145(21):2460-2472.
-
The complement system and kidney cancer: pathogenesis to clinical applications. J Clin Invest. 2025 May 01; 135(9).
-
Tumour interstitial fluid-enriched phosphoethanolamine suppresses T cell function. Nat Cell Biol. 2025 May; 27(5):835-846.
-
Designing live bacterial therapeutics for cancer. Adv Drug Deliv Rev. 2025 Jun; 221:115579.
-
PKCd Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid Cells. Cancer Immunol Res. 2025 Apr 02; 13(4):547-559.
-
The Impact of the Tumor Microenvironment on the Effect of IL-1ß Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials. Cancer Res Commun. 2025 04 01; 5(4):632-646.
-
Neutrophil extracellular traps promote pre-metastatic niche formation in the omentum by expanding innate-like B cells that express IL-10. Cancer Cell. 2025 Jan 13; 43(1):69-85.e11.
-
Engineered GM-CSF polarizes protumorigenic tumor-associated macrophages to an antitumorigenic phenotype and potently synergizes with IL-12 immunotherapy. J Immunother Cancer. 2024 Dec 22; 12(12).
-
Macrophages make "sense" of obesity-driven acidity in the TME. Cell Chem Biol. 2024 Dec 19; 31(12):2021-2023.